 Francisco La Rosa
Concepts (412)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 21 | 2022 | 1024 | 2.310 |
Why?
| | Urinary Bladder Neoplasms | 6 | 2024 | 253 | 1.470 |
Why?
| | Prostate | 9 | 2022 | 171 | 1.320 |
Why?
| | Testicular Neoplasms | 2 | 2026 | 111 | 1.030 |
Why?
| | Testicular Diseases | 1 | 2026 | 7 | 0.980 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2026 | 14 | 0.980 |
Why?
| | Histiocytosis, Sinus | 1 | 2026 | 9 | 0.980 |
Why?
| | Kidney Neoplasms | 9 | 2014 | 391 | 0.940 |
Why?
| | Prostatectomy | 9 | 2022 | 99 | 0.670 |
Why?
| | Carcinoma, Papillary | 3 | 2015 | 77 | 0.590 |
Why?
| | Adenocarcinoma | 4 | 2014 | 944 | 0.560 |
Why?
| | Solitary Fibrous Tumors | 1 | 2017 | 5 | 0.530 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2015 | 57 | 0.530 |
Why?
| | Spectrum Analysis | 1 | 2016 | 90 | 0.490 |
Why?
| | Carcinoma, Renal Cell | 3 | 2013 | 211 | 0.490 |
Why?
| | Biopsy | 8 | 2019 | 1086 | 0.440 |
Why?
| | Thyroid Gland | 8 | 1992 | 91 | 0.440 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2014 | 72 | 0.420 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 8 | 0.420 |
Why?
| | Lung Neoplasms | 3 | 2026 | 2508 | 0.420 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 17 | 0.410 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2015 | 645 | 0.390 |
Why?
| | Neoplasm Invasiveness | 5 | 2024 | 514 | 0.360 |
Why?
| | Biopsy, Needle | 5 | 2016 | 188 | 0.360 |
Why?
| | Cystectomy | 2 | 2024 | 40 | 0.350 |
Why?
| | Diagnosis, Differential | 6 | 2026 | 1474 | 0.340 |
Why?
| | Neoplasm Grading | 6 | 2022 | 303 | 0.340 |
Why?
| | Urothelium | 3 | 2015 | 38 | 0.330 |
Why?
| | Lymph Node Excision | 2 | 2024 | 171 | 0.330 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2021 | 77 | 0.320 |
Why?
| | Male | 49 | 2026 | 67419 | 0.320 |
Why?
| | Cyclic AMP | 7 | 2000 | 217 | 0.310 |
Why?
| | Mediastinal Diseases | 1 | 2007 | 9 | 0.280 |
Why?
| | Carcinoid Tumor | 1 | 2007 | 23 | 0.280 |
Why?
| | Neuroblastoma | 8 | 2010 | 160 | 0.270 |
Why?
| | Aged | 17 | 2024 | 23838 | 0.260 |
Why?
| | Parotid Gland | 6 | 1997 | 21 | 0.250 |
Why?
| | Ubiquitins | 4 | 2000 | 37 | 0.240 |
Why?
| | Orchiectomy | 1 | 2026 | 73 | 0.240 |
Why?
| | Sarcoidosis | 1 | 2007 | 156 | 0.240 |
Why?
| | Cell Division | 6 | 2000 | 788 | 0.230 |
Why?
| | Humans | 52 | 2026 | 136960 | 0.230 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2026 | 100 | 0.230 |
Why?
| | Sphingosine | 1 | 2025 | 45 | 0.230 |
Why?
| | Neoplasm Staging | 4 | 2024 | 1369 | 0.220 |
Why?
| | Lysophospholipids | 1 | 2025 | 80 | 0.220 |
Why?
| | Mitochondria, Heart | 1 | 2025 | 100 | 0.220 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2025 | 135 | 0.210 |
Why?
| | Perfusion | 1 | 2025 | 217 | 0.210 |
Why?
| | Lymphatic Diseases | 2 | 2009 | 23 | 0.210 |
Why?
| | Finasteride | 3 | 2008 | 35 | 0.210 |
Why?
| | Myocardial Contraction | 1 | 2025 | 296 | 0.210 |
Why?
| | Image-Guided Biopsy | 2 | 2012 | 37 | 0.200 |
Why?
| | Cell Transplantation | 3 | 1997 | 38 | 0.190 |
Why?
| | Major Histocompatibility Complex | 5 | 1990 | 230 | 0.190 |
Why?
| | Urinary Bladder | 2 | 2014 | 183 | 0.180 |
Why?
| | Prostate-Specific Antigen | 7 | 2020 | 160 | 0.180 |
Why?
| | Antigens, Polyomavirus Transforming | 3 | 1998 | 18 | 0.180 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 23 | 0.180 |
Why?
| | Seminoma | 1 | 2021 | 20 | 0.170 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1726 | 0.170 |
Why?
| | Graft Rejection | 8 | 1990 | 573 | 0.170 |
Why?
| | Biomarkers, Tumor | 3 | 2020 | 1250 | 0.170 |
Why?
| | Middle Aged | 18 | 2024 | 33242 | 0.170 |
Why?
| | Teratoma | 1 | 2021 | 116 | 0.160 |
Why?
| | Imaging, Three-Dimensional | 2 | 2015 | 552 | 0.160 |
Why?
| | H-2 Antigens | 4 | 1992 | 115 | 0.160 |
Why?
| | Pyrroles | 2 | 2013 | 213 | 0.160 |
Why?
| | Support Vector Machine | 2 | 2016 | 37 | 0.150 |
Why?
| | Islets of Langerhans Transplantation | 5 | 1992 | 64 | 0.150 |
Why?
| | Liver Cirrhosis, Experimental | 1 | 2019 | 11 | 0.150 |
Why?
| | Perilipin-2 | 1 | 2019 | 41 | 0.150 |
Why?
| | Heart Transplantation | 1 | 2025 | 689 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2024 | 388 | 0.140 |
Why?
| | Cell Transformation, Viral | 2 | 1997 | 25 | 0.140 |
Why?
| | Nephrectomy | 3 | 2014 | 156 | 0.140 |
Why?
| | Antineoplastic Agents | 5 | 2013 | 2126 | 0.140 |
Why?
| | Histocompatibility Antigens | 4 | 1988 | 106 | 0.140 |
Why?
| | Amyloid beta-Peptides | 5 | 2000 | 219 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 214 | 0.140 |
Why?
| | Hepatocytes | 1 | 2019 | 217 | 0.140 |
Why?
| | Tumor Burden | 2 | 2017 | 308 | 0.140 |
Why?
| | Indoles | 2 | 2013 | 408 | 0.140 |
Why?
| | Factor X Deficiency | 1 | 1997 | 4 | 0.130 |
Why?
| | Rodenticides | 1 | 1997 | 5 | 0.130 |
Why?
| | Hydatidiform Mole | 1 | 1997 | 4 | 0.130 |
Why?
| | Pregnancy, High-Risk | 1 | 1997 | 13 | 0.130 |
Why?
| | 4-Hydroxycoumarins | 1 | 1997 | 4 | 0.130 |
Why?
| | Colonic Pouches | 1 | 2017 | 15 | 0.130 |
Why?
| | Graft Survival | 5 | 1996 | 523 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 1 | 2019 | 328 | 0.130 |
Why?
| | Prognosis | 5 | 2019 | 3979 | 0.130 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1911 | 0.130 |
Why?
| | Maternal Age | 1 | 1997 | 127 | 0.130 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2019 | 321 | 0.130 |
Why?
| | Genital Neoplasms, Male | 1 | 2016 | 5 | 0.130 |
Why?
| | Granular Cell Tumor | 1 | 2016 | 7 | 0.130 |
Why?
| | HIV Seropositivity | 1 | 1997 | 125 | 0.130 |
Why?
| | alpha-Amylases | 4 | 1995 | 16 | 0.120 |
Why?
| | Scrotum | 1 | 2016 | 25 | 0.120 |
Why?
| | Uterine Neoplasms | 1 | 1997 | 110 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 278 | 0.120 |
Why?
| | Mice | 24 | 2025 | 17757 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1997 | 256 | 0.110 |
Why?
| | Cystotomy | 1 | 2014 | 4 | 0.110 |
Why?
| | Prostatitis | 1 | 2014 | 18 | 0.110 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2014 | 40 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 151 | 0.110 |
Why?
| | Animals | 34 | 2025 | 36934 | 0.110 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 56 | 0.110 |
Why?
| | Adult | 15 | 2024 | 37690 | 0.110 |
Why?
| | Adrenergic beta-Agonists | 2 | 1995 | 95 | 0.110 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 840 | 0.100 |
Why?
| | Optics and Photonics | 1 | 2014 | 43 | 0.100 |
Why?
| | Risk Assessment | 2 | 2020 | 3462 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 168 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 1997 | 254 | 0.100 |
Why?
| | Neurons | 6 | 1999 | 1585 | 0.100 |
Why?
| | Tumor Cells, Cultured | 8 | 2000 | 948 | 0.100 |
Why?
| | Abortion, Habitual | 1 | 1992 | 5 | 0.100 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2012 | 13 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2017 | 10715 | 0.100 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1992 | 11 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 4 | 2017 | 2677 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2015 | 242 | 0.100 |
Why?
| | Culture Media | 4 | 1994 | 163 | 0.100 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2014 | 11 | 0.100 |
Why?
| | Niacinamide | 1 | 2013 | 82 | 0.100 |
Why?
| | Phenylurea Compounds | 1 | 2013 | 97 | 0.090 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 267 | 0.090 |
Why?
| | Carcinoma, Basal Cell | 1 | 2013 | 74 | 0.090 |
Why?
| | Immune Tolerance | 2 | 1992 | 364 | 0.090 |
Why?
| | Organ Culture Techniques | 2 | 1992 | 154 | 0.090 |
Why?
| | Angiomyolipoma | 1 | 2011 | 23 | 0.090 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 19 | 0.090 |
Why?
| | Triiodothyronine | 1 | 2011 | 42 | 0.090 |
Why?
| | Sarcoma | 1 | 2013 | 184 | 0.090 |
Why?
| | Immunoglobulin A | 1 | 1992 | 211 | 0.090 |
Why?
| | Immunoglobulin M | 1 | 1992 | 289 | 0.090 |
Why?
| | HIV-1 | 1 | 1997 | 860 | 0.090 |
Why?
| | Thyroxine | 1 | 2011 | 62 | 0.090 |
Why?
| | NF-kappa B | 1 | 2014 | 676 | 0.080 |
Why?
| | Hypothyroidism | 1 | 2011 | 71 | 0.080 |
Why?
| | Thrombocytopenia | 1 | 1992 | 198 | 0.080 |
Why?
| | Mice, Inbred Strains | 6 | 1992 | 409 | 0.080 |
Why?
| | Antigens | 1 | 1992 | 353 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 237 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 661 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 525 | 0.080 |
Why?
| | Rats | 12 | 2000 | 5541 | 0.080 |
Why?
| | Cystitis | 1 | 2009 | 21 | 0.080 |
Why?
| | Organ Size | 3 | 2019 | 472 | 0.080 |
Why?
| | Thrombosis | 1 | 1992 | 370 | 0.070 |
Why?
| | Neurotoxins | 2 | 1998 | 28 | 0.070 |
Why?
| | Cyclosporine | 2 | 2000 | 268 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1990 | 365 | 0.070 |
Why?
| | Referral and Consultation | 2 | 2011 | 780 | 0.070 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2008 | 20 | 0.070 |
Why?
| | Female | 17 | 2024 | 73054 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 1992 | 893 | 0.070 |
Why?
| | Intestinal Perforation | 1 | 2008 | 45 | 0.070 |
Why?
| | Transplantation Immunology | 1 | 1988 | 32 | 0.070 |
Why?
| | Graft Enhancement, Immunologic | 1 | 1987 | 1 | 0.070 |
Why?
| | Chemoprevention | 1 | 2008 | 92 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2024 | 7596 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2007 | 114 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 3 | 2015 | 3541 | 0.070 |
Why?
| | Lymphatic Metastasis | 2 | 2024 | 341 | 0.070 |
Why?
| | Minor Histocompatibility Loci | 1 | 1987 | 4 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 4 | 2013 | 381 | 0.070 |
Why?
| | Anticarcinogenic Agents | 1 | 2007 | 77 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 903 | 0.060 |
Why?
| | Kidney Diseases, Cystic | 1 | 2006 | 24 | 0.060 |
Why?
| | Staining and Labeling | 3 | 2013 | 153 | 0.060 |
Why?
| | Cohort Studies | 2 | 2020 | 5679 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 6 | 1998 | 2464 | 0.060 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5753 | 0.060 |
Why?
| | Amyloid beta-Protein Precursor | 3 | 2000 | 66 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2013 | 849 | 0.060 |
Why?
| | Obesity | 1 | 2019 | 3028 | 0.060 |
Why?
| | Transplantation, Homologous | 5 | 1992 | 411 | 0.060 |
Why?
| | Syndrome | 2 | 2021 | 369 | 0.060 |
Why?
| | Cell Line, Transformed | 4 | 1998 | 144 | 0.060 |
Why?
| | Cell Differentiation | 5 | 2000 | 1985 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2264 | 0.060 |
Why?
| | Dopamine | 2 | 1998 | 303 | 0.050 |
Why?
| | Culture Techniques | 3 | 1990 | 73 | 0.050 |
Why?
| | Alprostadil | 3 | 1999 | 32 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 341 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2024 | 671 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1871 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2015 | 252 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 872 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 420 | 0.050 |
Why?
| | Reproducibility of Results | 3 | 2014 | 3247 | 0.050 |
Why?
| | CD4 Antigens | 2 | 1992 | 140 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 39 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4283 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 133 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1992 | 174 | 0.040 |
Why?
| | Aluminum | 1 | 2000 | 41 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2006 | 640 | 0.040 |
Why?
| | Peptidylprolyl Isomerase | 1 | 1999 | 9 | 0.040 |
Why?
| | Perineum | 1 | 2019 | 31 | 0.040 |
Why?
| | RNA, Messenger | 6 | 1999 | 2797 | 0.040 |
Why?
| | Adenylyl Cyclases | 2 | 1996 | 63 | 0.040 |
Why?
| | Fetal Tissue Transplantation | 1 | 1998 | 36 | 0.040 |
Why?
| | Cells, Cultured | 7 | 1998 | 4133 | 0.040 |
Why?
| | Prostaglandins | 1 | 1998 | 96 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2015 | 15619 | 0.040 |
Why?
| | Prostaglandins A | 1 | 1998 | 9 | 0.040 |
Why?
| | Radiometry | 1 | 2018 | 50 | 0.040 |
Why?
| | Growth Inhibitors | 1 | 1998 | 43 | 0.040 |
Why?
| | CD8 Antigens | 3 | 1992 | 74 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2018 | 264 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 71 | 0.030 |
Why?
| | Lung Diseases, Obstructive | 1 | 1997 | 48 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2018 | 138 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2019 | 250 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 134 | 0.030 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 1997 | 48 | 0.030 |
Why?
| | Vitamin K 1 | 1 | 1997 | 3 | 0.030 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 1 | 1997 | 16 | 0.030 |
Why?
| | Prothrombin Time | 1 | 1997 | 35 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 1999 | 462 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1997 | 54 | 0.030 |
Why?
| | Point Mutation | 1 | 1997 | 238 | 0.030 |
Why?
| | Isoproterenol | 2 | 1994 | 99 | 0.030 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 1996 | 72 | 0.030 |
Why?
| | Brain | 2 | 1998 | 2703 | 0.030 |
Why?
| | Mesencephalon | 1 | 1996 | 66 | 0.030 |
Why?
| | Alzheimer Disease | 2 | 2000 | 567 | 0.030 |
Why?
| | Hysterectomy | 1 | 1997 | 128 | 0.030 |
Why?
| | Bronchi | 1 | 1997 | 263 | 0.030 |
Why?
| | Islets of Langerhans | 3 | 1992 | 794 | 0.030 |
Why?
| | Mouth Mucosa | 1 | 1996 | 92 | 0.030 |
Why?
| | Glioma | 1 | 2000 | 396 | 0.030 |
Why?
| | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 3 | 2000 | 3 | 0.030 |
Why?
| | Corpus Striatum | 1 | 1997 | 170 | 0.030 |
Why?
| | Lymphocytes | 2 | 1988 | 390 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 1996 | 150 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2000 | 863 | 0.030 |
Why?
| | Prostatic Hyperplasia | 1 | 2015 | 42 | 0.030 |
Why?
| | Adenoma, Pleomorphic | 1 | 1994 | 10 | 0.030 |
Why?
| | Parotid Neoplasms | 1 | 1994 | 15 | 0.030 |
Why?
| | Mice, Inbred BALB C | 3 | 1989 | 1269 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 688 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2019 | 644 | 0.030 |
Why?
| | Genetic Variation | 1 | 2019 | 1000 | 0.030 |
Why?
| | Wavelet Analysis | 1 | 2014 | 7 | 0.030 |
Why?
| | Atrophy | 1 | 2014 | 188 | 0.030 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 97 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 79 | 0.030 |
Why?
| | Terbutaline | 1 | 1993 | 8 | 0.030 |
Why?
| | Dobutamine | 1 | 1993 | 26 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 78 | 0.030 |
Why?
| | Breeding | 1 | 2013 | 64 | 0.030 |
Why?
| | Needles | 1 | 2014 | 60 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 95 | 0.030 |
Why?
| | Glucose | 1 | 2019 | 1029 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1996 | 499 | 0.030 |
Why?
| | Phenotype | 2 | 2019 | 3148 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 2 | 1992 | 417 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.020 |
Why?
| | Keratins | 1 | 2013 | 171 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.020 |
Why?
| | Organ Specificity | 1 | 2013 | 305 | 0.020 |
Why?
| | Kallikreins | 1 | 2012 | 28 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 194 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 120 | 0.020 |
Why?
| | Lymphocyte Activation | 3 | 1992 | 1134 | 0.020 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2014 | 152 | 0.020 |
Why?
| | Health Surveys | 1 | 2014 | 518 | 0.020 |
Why?
| | Parkinson Disease | 1 | 1998 | 528 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 1996 | 593 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 124 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 506 | 0.020 |
Why?
| | Pregnancy | 2 | 1997 | 6725 | 0.020 |
Why?
| | Minor Histocompatibility Antigens | 1 | 1992 | 47 | 0.020 |
Why?
| | Time Factors | 2 | 1996 | 6786 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 1991 | 1979 | 0.020 |
Why?
| | Antigens, CD | 1 | 2014 | 527 | 0.020 |
Why?
| | Clone Cells | 3 | 1996 | 265 | 0.020 |
Why?
| | Cell Line | 2 | 1994 | 2857 | 0.020 |
Why?
| | Actins | 1 | 1993 | 415 | 0.020 |
Why?
| | Macrophages | 1 | 2019 | 1548 | 0.020 |
Why?
| | Risk Factors | 2 | 2019 | 10367 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1228 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 852 | 0.020 |
Why?
| | Lymphokines | 1 | 1990 | 132 | 0.020 |
Why?
| | Smoking | 1 | 1997 | 1608 | 0.020 |
Why?
| | Laparoscopy | 1 | 2014 | 450 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 869 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2000 | 75 | 0.020 |
Why?
| | Inflammation | 2 | 1998 | 2830 | 0.020 |
Why?
| | Proteins | 1 | 1995 | 1008 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 603 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1991 | 193 | 0.020 |
Why?
| | Recurrence | 1 | 1992 | 1057 | 0.020 |
Why?
| | Nephrolithiasis | 1 | 2009 | 10 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 971 | 0.020 |
Why?
| | Metaplasia | 1 | 2009 | 60 | 0.020 |
Why?
| | Interferon-gamma | 2 | 1990 | 785 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 656 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 1992 | 407 | 0.020 |
Why?
| | Interferons | 1 | 1990 | 202 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1073 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1870 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2007 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2150 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 298 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5522 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 195 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 320 | 0.020 |
Why?
| | Immunologic Memory | 1 | 1990 | 354 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1480 | 0.020 |
Why?
| | Bucladesine | 2 | 1998 | 24 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1989 | 203 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2015 | 0.020 |
Why?
| | Adolescent | 2 | 2016 | 21463 | 0.020 |
Why?
| | Medical History Taking | 1 | 2007 | 117 | 0.020 |
Why?
| | Bias | 1 | 2007 | 222 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 1992 | 699 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 555 | 0.020 |
Why?
| | Endocrine Glands | 1 | 1986 | 16 | 0.020 |
Why?
| | Radiography | 1 | 2008 | 816 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 510 | 0.020 |
Why?
| | Culture Media, Serum-Free | 2 | 1998 | 46 | 0.010 |
Why?
| | Physicians | 1 | 2014 | 918 | 0.010 |
Why?
| | Hypersensitivity, Delayed | 1 | 1985 | 28 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2465 | 0.010 |
Why?
| | Cell Survival | 1 | 1988 | 1123 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3410 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1985 | 157 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2011 | 3548 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 13202 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1062 | 0.010 |
Why?
| | Testosterone | 1 | 2007 | 412 | 0.010 |
Why?
| | Early Detection of Cancer | 1 | 2008 | 464 | 0.010 |
Why?
| | Cross Reactions | 1 | 1983 | 130 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1983 | 268 | 0.010 |
Why?
| | Colorado | 1 | 2012 | 4515 | 0.010 |
Why?
| | Logistic Models | 1 | 2007 | 2071 | 0.010 |
Why?
| | Lymphocyte Depletion | 2 | 1992 | 136 | 0.010 |
Why?
| | Transfection | 2 | 1994 | 935 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1697 | 0.010 |
Why?
| | Incidence | 1 | 2007 | 2801 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 7511 | 0.010 |
Why?
| | Alum Compounds | 1 | 2000 | 23 | 0.010 |
Why?
| | Neurites | 1 | 2000 | 48 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1983 | 704 | 0.010 |
Why?
| | Carotenoids | 1 | 1999 | 43 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2007 | 2803 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 5072 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1997 | 25 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 66 | 0.010 |
Why?
| | Codon | 1 | 1997 | 90 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 972 | 0.010 |
Why?
| | Simian virus 40 | 1 | 1996 | 24 | 0.010 |
Why?
| | Transplantation, Heterotopic | 1 | 1996 | 18 | 0.010 |
Why?
| | Butyric Acid | 1 | 1996 | 7 | 0.010 |
Why?
| | Epithelium | 1 | 1997 | 314 | 0.010 |
Why?
| | Xerostomia | 1 | 1996 | 16 | 0.010 |
Why?
| | Oxidopamine | 1 | 1996 | 16 | 0.010 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 1 | 1996 | 19 | 0.010 |
Why?
| | Protein Kinase C beta | 1 | 1996 | 20 | 0.010 |
Why?
| | Carbocyanines | 1 | 1996 | 32 | 0.010 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1996 | 26 | 0.010 |
Why?
| | Exons | 1 | 1997 | 350 | 0.010 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1996 | 19 | 0.010 |
Why?
| | Stereotyped Behavior | 1 | 1996 | 19 | 0.010 |
Why?
| | Nestin | 1 | 1996 | 19 | 0.010 |
Why?
| | Intermediate Filament Proteins | 1 | 1996 | 56 | 0.010 |
Why?
| | Proline-Rich Protein Domains | 1 | 1995 | 2 | 0.010 |
Why?
| | Protein Kinase C-delta | 1 | 1996 | 48 | 0.010 |
Why?
| | Muscarinic Agonists | 1 | 1995 | 16 | 0.010 |
Why?
| | Salivary Proteins and Peptides | 1 | 1995 | 14 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1992 | 3670 | 0.010 |
Why?
| | Adrenergic alpha-Agonists | 1 | 1995 | 27 | 0.010 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 1996 | 58 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2000 | 690 | 0.010 |
Why?
| | Cells, Immobilized | 1 | 1995 | 21 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1996 | 65 | 0.010 |
Why?
| | Butyrates | 1 | 1996 | 60 | 0.010 |
Why?
| | Methamphetamine | 1 | 1996 | 65 | 0.010 |
Why?
| | Isoenzymes | 1 | 1996 | 304 | 0.010 |
Why?
| | Immunoblotting | 1 | 1995 | 304 | 0.010 |
Why?
| | Protein Kinase C | 1 | 1996 | 254 | 0.010 |
Why?
| | Antibodies, Monoclonal | 2 | 1992 | 1414 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 1996 | 315 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1994 | 253 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1992 | 135 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1635 | 0.010 |
Why?
| | Mice, Nude | 1 | 1994 | 695 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1996 | 964 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1996 | 735 | 0.010 |
Why?
| | Blotting, Western | 1 | 1994 | 1218 | 0.010 |
Why?
| | Plasmids | 1 | 1992 | 358 | 0.010 |
Why?
| | Models, Biological | 2 | 1991 | 1777 | 0.010 |
Why?
| | Mice, Inbred NOD | 1 | 1992 | 596 | 0.010 |
Why?
| | Spleen | 1 | 1992 | 515 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 1991 | 303 | 0.010 |
Why?
| | Interleukin-3 | 1 | 1990 | 25 | 0.010 |
Why?
| | Lymph Nodes | 1 | 1992 | 487 | 0.010 |
Why?
| | United States | 1 | 2007 | 14894 | 0.010 |
Why?
| | Peptides | 1 | 1995 | 975 | 0.000 |
Why?
| | Flow Cytometry | 1 | 1992 | 1194 | 0.000 |
Why?
| | Interleukin-2 | 1 | 1990 | 453 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1992 | 1096 | 0.000 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1990 | 1233 | 0.000 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1990 | 1084 | 0.000 |
Why?
| | Blood Glucose | 1 | 1992 | 2184 | 0.000 |
Why?
|
|
La Rosa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|